| Q58050808 | 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis |
| Q90668344 | A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients |
| Q48930090 | A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma. |
| Q37112857 | A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. |
| Q46440869 | A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control |
| Q34383712 | A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors |
| Q58010986 | Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study |
| Q42777304 | Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. |
| Q36498366 | Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. |
| Q41984297 | Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma |
| Q45973697 | Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. |
| Q38768069 | Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO). |
| Q39974408 | BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia |
| Q53109992 | Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. |
| Q33364213 | Bortezomib is an efficient agent in plasma cell leukemias |
| Q60203808 | Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study |
| Q46717021 | Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression |
| Q60203634 | Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m |
| Q34543082 | CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features |
| Q39399792 | CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype |
| Q60203939 | Chromosomal abnormalities are related to location and grade of osteoarthritis |
| Q60204022 | Chromosomal imbalances identified by comparative genomic hybridization in sporadic parathyroid adenomas |
| Q60203477 | Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients |
| Q35180069 | Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r |
| Q30571858 | Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project |
| Q101133052 | Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma |
| Q60203595 | Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma |
| Q36500714 | Conventional diagnostics in multiple myeloma |
| Q60204139 | Correspondence |
| Q41827707 | Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells |
| Q38707040 | DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma |
| Q38789282 | Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials |
| Q28544696 | Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability |
| Q34091328 | Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. |
| Q60203403 | Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile |
| Q60204034 | Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization |
| Q33712516 | Differentiation stage of myeloma plasma cells: biological and clinical significance. |
| Q60204043 | Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification |
| Q52668514 | Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. |
| Q51703229 | Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma. |
| Q46415118 | Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response. |
| Q28296718 | Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma |
| Q41417468 | Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair |
| Q41177165 | From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation |
| Q38331348 | Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. |
| Q28285016 | Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals |
| Q60203873 | Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma |
| Q60203892 | Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics |
| Q44097865 | Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes. |
| Q92444518 | Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder |
| Q41847877 | Genomic analysis of high-risk smoldering multiple myeloma. |
| Q59305395 | Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain |
| Q60203901 | Hematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11 |
| Q60203947 | Heterogeneity of structural abnormalities in the 7q31.3∼q34 region in myeloid malignancies |
| Q40316913 | High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma. |
| Q60203492 | High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma |
| Q60204131 | IL-4 improves the detection of cytogenetic abnormalities in multiple myeloma and increases the proportion of clonally abnormal metaphases |
| Q58051480 | Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling |
| Q40614547 | Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents |
| Q44592635 | Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta |
| Q60203506 | Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression |
| Q60203910 | Immunophenotypic and Cytogenetic Comparison of Waldenström's Macroglobulinemia with Splenic Marginal Zone Lymphoma |
| Q46640315 | Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. |
| Q36595290 | Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. |
| Q33268092 | In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions |
| Q48090885 | In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins. |
| Q38968027 | In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. |
| Q54510843 | Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement. |
| Q47791159 | Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications. |
| Q28253748 | Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma |
| Q34259262 | Integration of global spectral karyotyping, CGH arrays, and expression arrays reveals important genes in the pathogenesis of glioblastoma multiforme |
| Q42089762 | Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse. |
| Q34241661 | International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. |
| Q37564751 | Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms |
| Q54541357 | Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. |
| Q54270566 | MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. |
| Q60203531 | Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial |
| Q60203690 | Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors |
| Q35496723 | MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL. |
| Q54789519 | Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. |
| Q40780088 | Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients |
| Q58051526 | Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes |
| Q28074490 | Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma |
| Q36987485 | Molecular biology of myeloma. |
| Q34034713 | Molecular characterization of the region 7q22.1 in splenic marginal zone lymphomas |
| Q89582276 | Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients |
| Q33392209 | Monoclonal free light chains can be found in heavy chain diseases. |
| Q60204086 | Monocyte counts: an early index of haemopoietic reconstitution after peripheral blood stem cell transplantation |
| Q38484493 | Multicolor fluorescence in situ hybridization studies in multiple myeloma and monoclonal gammopathy of undetermined significance. |
| Q45251392 | Multifunctional role of Erk5 in multiple myeloma |
| Q60203544 | Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials |
| Q36969778 | Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation |
| Q51327366 | Multiple cranial neuropathy and intracranial hypertension associated with all-trans retinoic acid treatment in a young adult patient with acute promyelocytic leukemia. |
| Q43841500 | Neurological complications after autologous stem cell transplantation |
| Q35842194 | Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. |
| Q39003105 | Origin of Waldenstrom's macroglobulinaemia |
| Q51533765 | Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. |
| Q35944673 | Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q. |
| Q60203654 | P53deletion may drive the clinical evolution and treatment response in multiple myeloma |
| Q60204014 | Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities |
| Q53840420 | Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma. |
| Q33376498 | Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. |
| Q60203335 | Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential |
| Q35128148 | Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines |
| Q60203295 | Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis |
| Q38837705 | Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma |
| Q41088379 | Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair |
| Q60203750 | Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy |
| Q47238301 | Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma |
| Q60203798 | Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated |
| Q58760132 | Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials |
| Q38645307 | Quantitative PCR: an alternative approach to detect common copy number alterations in multiple myeloma |
| Q33816012 | Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma |
| Q90898528 | Reply to Brown et al: 'Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis' |
| Q60203964 | Reply to Wan et al |
| Q36133050 | Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders |
| Q33402403 | Response to imatinib mesylate in patients with hypereosinophilic syndrome. |
| Q36862536 | Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication |
| Q37654397 | Risk stratification in the era of novel therapies. |
| Q59602388 | SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status |
| Q60203306 | Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM |
| Q58498450 | Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving α4β1 integrin function |
| Q38751108 | Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone. |
| Q33705389 | Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival |
| Q38839531 | The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care |
| Q60203614 | The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells |
| Q41473438 | The cellular origin and malignant transformation of Waldenström macroglobulinemia. |
| Q57213375 | The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights |
| Q60203160 | The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia |
| Q40272775 | The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. |
| Q47873839 | The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma. |
| Q60203704 | The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients |
| Q53643731 | The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. |
| Q42940532 | The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. |
| Q33978937 | Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. |
| Q44004521 | Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma |
| Q60203758 | Transient t(11;17)(q14;q12) in patient with chronic myelogenous leukemia in complete molecular response |
| Q49898996 | Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study. |
| Q42123569 | Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients |
| Q34460989 | Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. |
| Q39590174 | Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. |